Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Taranabant
open-in-new
<p>Taranabant (codenamed MK-0364) is a <a href="/facts/Cannabinoid_receptor_type_1/7b2tfePV"> cannabinoid receptor type 1 (CB1)</a> <a href="/facts/Inverse_agonist/NDLoA789">inverse agonist</a> that was investigated as a potential treatment for <a href="/facts/Obesity/RBF9y5Vl">obesity</a> due to its <a href="/facts/Anorectic/MuLF8GNo">anorectic</a> effects. It was developed by <a href="/facts/Merck_%26_Co./8YD8dvwR">Merck & Co.</a> </p><p>In October 2008, Merck stopped its <a href="/facts/Clinical_trials/q8LMr832">phase III</a> <a href="/facts/Clinical_trials/q8LMr832">clinical trials</a> with the drug due to high level of <a href="/facts/Central_nervous_system/k8I6To97">central nervous system</a> side effects, mainly <a href="/facts/Depression_(mood)/GDNFWm1L">depression</a> and <a href="/facts/Anxiety/Geekl883">anxiety</a>. </p>